Historical Valuation
Autolus Therapeutics PLC (AUTL) is now in the Fair zone, suggesting that its current forward PS ratio of 3.76 is considered Fairly compared with the five-year average of -3.04. The fair price of Autolus Therapeutics PLC (AUTL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.91
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Autolus Therapeutics PLC (AUTL) has a current Price-to-Book (P/B) ratio of 1.87. Compared to its 3-year average P/B ratio of 2.45 , the current P/B ratio is approximately -23.42% higher. Relative to its 5-year average P/B ratio of 2.04, the current P/B ratio is about -8.25% higher. Autolus Therapeutics PLC (AUTL) has a Forward Free Cash Flow (FCF) yield of approximately -57.31%. Compared to its 3-year average FCF yield of -34.93%, the current FCF yield is approximately 64.07% lower. Relative to its 5-year average FCF yield of -36.50% , the current FCF yield is about 57.03% lower.
P/B
Median3y
2.45
Median5y
2.04
FCF Yield
Median3y
-34.93
Median5y
-36.50
Competitors Valuation Multiple
AI Analysis for AUTL
The average P/S ratio for AUTL competitors is 1.51, providing a benchmark for relative valuation. Autolus Therapeutics PLC Corp (AUTL.O) exhibits a P/S ratio of 3.76, which is 150.02% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AUTL
1Y
3Y
5Y
Market capitalization of AUTL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AUTL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AUTL currently overvalued or undervalued?
Autolus Therapeutics PLC (AUTL) is now in the Fair zone, suggesting that its current forward PS ratio of 3.76 is considered Fairly compared with the five-year average of -3.04. The fair price of Autolus Therapeutics PLC (AUTL) is between to according to relative valuation methord.
What is Autolus Therapeutics PLC (AUTL) fair value?
AUTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Autolus Therapeutics PLC (AUTL) is between to according to relative valuation methord.
How does AUTL's valuation metrics compare to the industry average?
The average P/S ratio for AUTL's competitors is 1.51, providing a benchmark for relative valuation. Autolus Therapeutics PLC Corp (AUTL) exhibits a P/S ratio of 3.76, which is 150.02% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Autolus Therapeutics PLC (AUTL) as of Jan 10 2026?
As of Jan 10 2026, Autolus Therapeutics PLC (AUTL) has a P/B ratio of 1.87. This indicates that the market values AUTL at 1.87 times its book value.
What is the current FCF Yield for Autolus Therapeutics PLC (AUTL) as of Jan 10 2026?
As of Jan 10 2026, Autolus Therapeutics PLC (AUTL) has a FCF Yield of -57.31%. This means that for every dollar of Autolus Therapeutics PLC’s market capitalization, the company generates -57.31 cents in free cash flow.
What is the current Forward P/E ratio for Autolus Therapeutics PLC (AUTL) as of Jan 10 2026?
As of Jan 10 2026, Autolus Therapeutics PLC (AUTL) has a Forward P/E ratio of -1.93. This means the market is willing to pay $-1.93 for every dollar of Autolus Therapeutics PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Autolus Therapeutics PLC (AUTL) as of Jan 10 2026?
As of Jan 10 2026, Autolus Therapeutics PLC (AUTL) has a Forward P/S ratio of 3.76. This means the market is valuing AUTL at $3.76 for every dollar of expected revenue over the next 12 months.